HomeAbout

TL;DR CNBC


Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says - TL;DR CNBC

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says

Publishing timestamp: 2023-11-27 18:24:51


Summary

The article discusses a large analysis of real-world data that shows Eli Lilly's Mounjaro is more effective for weight loss than Novo Nordisk's Ozempic in overweight or obese adults. The study found that patients taking Mounjaro were significantly more likely to lose weight and saw larger reductions in body weight compared to those on Ozempic. Both drugs are approved for the treatment of Type 2 diabetes but are also used off-label for weight loss. The study suggests that Mounjaro has an edge over Ozempic in a real-world setting, specifically among overweight or obese adults.


Sentiment: MIXED

Tickers: NOVO.B-DKLLY

Keywords: biotech and pharmaceuticalseli lilly and cosciencehealth care industrybiotechnologybusiness newspharmaceuticalsnovo nordisk a/sbusinessbreaking news

Source: https://www.cnbc.com/2023/11/27/mounjaro-superior-to-ozempic-for-weight-loss-study-says.html


Developed by Leo Phan